ATE452129T1 - N-phenyl-2-pyrimidine-amine derivatives - Google Patents

N-phenyl-2-pyrimidine-amine derivatives

Info

Publication number
ATE452129T1
ATE452129T1 AT01984640T AT01984640T ATE452129T1 AT E452129 T1 ATE452129 T1 AT E452129T1 AT 01984640 T AT01984640 T AT 01984640T AT 01984640 T AT01984640 T AT 01984640T AT E452129 T1 ATE452129 T1 AT E452129T1
Authority
AT
Austria
Prior art keywords
pyrimidine
phenyl
amine derivatives
preparation
medicaments
Prior art date
Application number
AT01984640T
Other languages
English (en)
Inventor
Hans Buerger
Giorgio Caravatti
Juerg Zimmermann
Paul Manley
Werner Breitenstein
Margaret Cudd
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE452129(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE452129T1 publication Critical patent/ATE452129T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT01984640T 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives ATE452129T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0022438.6A GB0022438D0 (en) 2000-09-13 2000-09-13 Organic Compounds
PCT/EP2001/010503 WO2002022597A1 (en) 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives

Publications (1)

Publication Number Publication Date
ATE452129T1 true ATE452129T1 (de) 2010-01-15

Family

ID=9899367

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01984640T ATE452129T1 (de) 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives

Country Status (14)

Country Link
US (3) US7081532B2 (de)
EP (1) EP1322634B1 (de)
JP (1) JP2004509111A (de)
CN (2) CN1872850A (de)
AT (1) ATE452129T1 (de)
AU (1) AU2002218167A1 (de)
BR (1) BR0113838A (de)
CA (2) CA2416274C (de)
DE (1) DE60140814D1 (de)
ES (1) ES2336891T3 (de)
GB (1) GB0022438D0 (de)
HK (1) HK1057752A1 (de)
PT (1) PT1322634E (de)
WO (1) WO2002022597A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
BRPI0312288B8 (pt) 2002-06-28 2021-05-25 Nippon Shinyaku Co Ltd derivados de amidas
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
DE60318089T2 (de) * 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. Protein-tyrosine-kinase-inhibitoren
AU2003232650A1 (en) * 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2004108699A1 (en) * 2003-06-06 2004-12-16 Natco Pharma Limited Process for the preparation of the anti-cancer drug imatinib and its analogues
EP1635835B1 (de) * 2003-06-13 2010-01-06 Novartis AG 2-aminopyrimidin-derivate als raf-kinase-hemmer
KR100848067B1 (ko) 2003-12-25 2008-07-23 니뽄 신야쿠 가부시키가이샤 아미드 유도체 및 의약
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
WO2006017353A2 (en) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES, as represented byTHE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of viral infections
AP2470A (en) 2004-09-09 2012-09-17 Natco Pharma Ltd Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US7939541B2 (en) * 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN1972917B (zh) * 2004-12-31 2010-08-25 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
US20080214445A1 (en) * 2005-06-23 2008-09-04 Sebastien Bihorel Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
JP5335426B2 (ja) * 2005-09-27 2013-11-06 アイアールエム・リミテッド・ライアビリティ・カンパニー ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用
US8067421B2 (en) * 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
WO2008027600A2 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Imatinib compositions
US8268809B2 (en) 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
EP1988089A1 (de) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib-Base und Imatinib-Mesylat und Herstellungsverfahren dafür
US20080103305A1 (en) * 2006-10-26 2008-05-01 Macdonald Peter Process for the preparation of imatinib
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2686378C (en) * 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
WO2008150481A2 (en) * 2007-05-29 2008-12-11 Sicor Inc. Processes for the preparation of crystalline form beta of imatinib mesylate
CA2689989A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
KR101218926B1 (ko) 2007-08-22 2013-01-04 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
EA017392B1 (ru) 2007-08-22 2012-12-28 Айрм Ллк Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2240175B1 (de) * 2008-02-11 2013-01-02 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Verbindungen mit mdr1-inverser aktivität
NZ587589A (en) * 2008-02-15 2012-10-26 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
CA2723961C (en) 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2727737C (en) * 2008-06-27 2016-08-23 Indiana University Research And Technology Corporation Materials and methods for suppressing and/or treating neurofibroma and related tumors
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
UY32562A (es) 2009-04-15 2010-11-30 Astrazeneca Ab Pirimidinas sustituidas por imidazol 724
WO2010120388A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8530492B2 (en) * 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
CN102212057B (zh) * 2011-04-13 2013-11-27 合肥工业大学 一种羧酸类非甾体抗炎药衍生物及其制备方法和用途
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
CN102796110B (zh) * 2011-05-23 2016-03-30 复旦大学 苯胺嘧啶化合物及其制备方法和用途
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN103044394A (zh) * 2012-12-20 2013-04-17 北京理工大学 一种苯基氨基嘧啶衍生物及其制备方法和用途
CN103058935B (zh) * 2013-01-15 2015-05-06 四川大学 一种嘧啶类化合物及其制备方法和用途
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN105859683B (zh) * 2016-04-11 2018-09-28 连云港恒运药业有限公司 伊马替尼的高纯度工业制备工艺
CN107805240A (zh) * 2016-09-08 2018-03-16 中国科学院合肥物质科学研究院 一种新型的pdgfr激酶抑制剂及其用途
CN107652266A (zh) * 2017-10-27 2018-02-02 上海应用技术大学 一种靶向酪氨酸激酶小分子抑制剂及其应用
SG11202109678RA (en) * 2019-03-05 2021-10-28 Hongyi & Ass Llc Compounds for treating neurodegenerative diseases and cancers
CN110078708B (zh) * 2019-05-08 2020-12-11 东南大学 Smo/Bcr-Abl双靶向抑制剂及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
DE60140814D1 (de) 2010-01-28
CN1872850A (zh) 2006-12-06
EP1322634A1 (de) 2003-07-02
CA2416274C (en) 2011-01-04
CA2416274A1 (en) 2002-03-21
BR0113838A (pt) 2003-06-03
EP1322634B1 (de) 2009-12-16
US20040102453A1 (en) 2004-05-27
PT1322634E (pt) 2010-02-22
ES2336891T3 (es) 2010-04-19
US7312216B2 (en) 2007-12-25
GB0022438D0 (en) 2000-11-01
JP2004509111A (ja) 2004-03-25
CN100406452C (zh) 2008-07-30
US20060223818A1 (en) 2006-10-05
WO2002022597A1 (en) 2002-03-21
CN1525967A (zh) 2004-09-01
US20070265292A1 (en) 2007-11-15
HK1057752A1 (en) 2004-04-16
CA2687476A1 (en) 2002-03-21
AU2002218167A1 (en) 2002-03-26
US7081532B2 (en) 2006-07-25
US7329661B2 (en) 2008-02-12

Similar Documents

Publication Publication Date Title
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
SE0101387D0 (sv) Novel compounds
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
TW200510392A (en) Chemical compounds
SE9900961D0 (sv) Novel compounds
TW200505452A (en) Chemical compounds
DE60001586D1 (de) Diphenyl-piperidin derivate
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
ATE325809T1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl- amino-5-phenyl-pentansäure
TW200504051A (en) Novel acridine derivatives and their use as medicaments
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1322634

Country of ref document: EP